Plain-English translation of NCT06494514 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether NALIRIFOX—a three-drug chemotherapy combination—works better than a standard two-drug combination (gemcitabine and albumin-paclitaxel) when paired with immunotherapy and targeted radiation therapy. Both groups will receive the same type of immune-boosting medication and radiation, but the chemotherapy drugs will be different. The goal is to see which combination works best and is safest for treating pancreatic cancer that is locally advanced (meaning it has grown beyond the pancreas but has not spread to distant organs).
Pancreatic cancer is very difficult to treat, and patients need better options. Doctors want to know if this newer chemotherapy combination, when combined with immunotherapy and radiation, can help patients live longer and with fewer side effects than the current standard treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two chemotherapy combinations over 6–8 cycles (each cycle is 3–4 weeks long). During your third cycle, you will also begin a specialized radiation therapy called SBRT, which delivers focused radiation to the tumor. Throughout the study, you will visit the clinic regularly to receive medications, have blood tests, and be monitored for side effects. The entire treatment period will take several months, and you will continue to be followed to see how well the treatment is working.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China